1. Home
  2. |Insights
  3. |FY 2019 NDAA – Cyber Focus

FY 2019 NDAA – Cyber Focus

Client Alert | 1 min read | 08.20.18

The 2019 National Defense Authorization Act (NDAA) includes a robust set of cybersecurity provisions impacting the Defense Industrial Base, including:

  • Encouraging federal agencies to avoid using lowest price technically acceptable source selection criteria in procurements predominately for the acquisition of information technology and cybersecurity services.
  • Establishing a pilot program to oversee Controlled Unclassified Information (CUI) handled by contractors with foreign ownership, control, or influence.
  • Requiring DoD to notify Congress of data breaches involving significant losses of Personally Identifiable Information (PII) or other forms of CUI.
  • Encouraging DoD and the National Institute of Standards and Technology (NIST) to assist small businesses in the Defense Industrial Supply Chain by enhancing cyber threat awareness and training, and helping to conduct voluntary cybersecurity self-assessments.
  • Requiring DoD to obtain disclosures from vendors regarding foreign government access to products or source codes, before acquiring their cybersecurity or information technology products and services.

Insights

Client Alert | 4 min read | 08.29.25

Gender-Affirming Care Targeted for Potential False Claims Act Enforcement

On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including  Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments....